Bedside to Bench: Epithelial Cell Reprogramming in Pulmonary Fibrosis

The field of interstitial lung diseases, with its alphabet soup of entities (IPF, NSIP, HP, and more), has seen significant progress in the past few years. Much of this progress has been catalyzed by a new understanding of the pathophysiology of ILD, including the role of cellular aging in pulmonary fibrosis. In this Grand Rounds, Tien Peng and Paul Wolters provide clinical updates in the management of patients with pulmonary fibrosis and describe emerging research on the role that epithelial cells and telomere dysfunction play in these often debilitating conditions.

Speakers
Tien Peng, MD, is a pulmonary physician-scientist who runs the innovative Peng Lab, which uses complex murine genetic models and human specimens to investigate how fibroblasts maintain organ homeostasis, initiate disease, and drive tissue aging.

Paul Wolters, MD, is a pulmonary physician-scientist who specializes in the diagnosis and care of patients with interstitial lung disease. His research investigates the molecular pathogenesis of fibrotic lung disease to help develop novel therapies.

Program
Bob Wachter: Introduction
2:30-24:10 — Paul Wolters, MD, pulmonary physician-scientist
24:10-42:00 — Tien Peng, MD, pulmonary physician-scientist
42:00-57:50 — Q&A

See previous Medical Grand Rounds:
May 2: An Immunotherapy Renaissance in Hepatobiliary Cancers
   • An Immunotherapy Renaissance in Hepat...  

April 25: Diagnosis: Teaching, Measuring, Innovating
   • Diagnosis: Teaching, Measuring, Innov...  

April 18: The Devastating Effect of Covid-19 on Patients with End-Stage Kidney Disease
   • The Devastating Effect of Covid-19 on...  

April 11: Immune Effector Cell Therapy in Hematologic Malignancies: Lessons Learned
   • Immune Effector Cell Therapy in Hemat...